Yale Cancer Center Smilow Cancer Hospital

EP. 31: Patient Scenario 2: 1L Management of ES-SCLC Positive for Synaptophysin With a Ki-67 Score of 90%

July 24th 2023

Expert oncologists present the case of a 45-year-old woman with synaptophysin-positive, extensive-stage small-cell lung cancer with a Ki-67 score of 90%, who is treated with carboplatin, etoposide, and atezolizumab in the first-line setting, and provide their initial impressions.

EP. 32: Real World Data for Combination Strategies With Chemotherapy and Immunotherapy in ES-SCLC

July 24th 2023

Faculty discuss real world data for treatment approaches using chemotherapy in combination with immunotherapy in extensive-stage small-cell lung cancer.

EP. 33: Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy

July 31st 2023

A panel of expert oncologists present the case of a 78-year-old woman who is treated with lurbinectedin following disease progress on first-line carboplatin, etoposide, and atezolizumab.

EP. 34: Evolving Treatment Strategies for SCLC in the Second-Line Setting and Beyond

July 31st 2023

Panel experts discuss evolving treatment options for small-cell lung cancer in the second-line setting and beyond.

EP. 35: LAGOON and IMFORTE Trials: Data Updates and Expert Insights

August 7th 2023

A review of the LAGOON and IMFORTE trials with expert insights regarding the potential clinical implications of current and future study findings.

EP. 36: 2L Dosing Considerations and Management Strategies for SCLC

August 7th 2023

Expert oncologists discuss important dosing considerations and treatment management strategies for lurbinectedin and other second-line therapy approaches in small-cell lung cancer.

EP. 37: Novel Treatment Approaches for SCLC and Future Perspectives

August 14th 2023

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.